跳到正文
EMA 官方医药监管信息·精选AI 评分83

ICH M13B 即释固体口服制剂额外规格生物等效豁免指南经 CHMP 最终通过(Step 5),2027 年 3 月 17 日生效

ICH M13B guideline on bioequivalence for immediate-release solid oral dosage forms - additional strengths biowaiver - Step 5

AI 导读

EMA 发布 ICH M13B 即释固体口服制剂额外规格生物等效豁免指南,CHMP 于 2026 年 9 月 17 日最终通过并进入 Step 5,该指南定于 2027 年 3 月 17 日生效。

推荐理由

文件列出多规格即释口服固体制剂生物等效豁免的判定条件与溶出相似性准则,可供申报时核对比对基准。

正文 · 原文

PDF 文字版;图形和原始排版请参阅官方 PDF。

第 1 页

17 September 2026
EMA/CHMP/ICH/85092/2025
Committee for Human Medicinal Products




ICH M13B Guideline on bioequivalence for immediate-
release solid oral dosage forms - additional strengths
biowaiver
Step 5



  Transmission to CHMP                                                                 13 March 2025

  Adoption by CHMP                                                                     27 March 2025

  Release for public consultation                                                      9 April 2025

  Deadline for comments                                                                9 July 2025

  Final adoption by CHMP                                                               17 September 2026

  Date for coming into effect                                                          17 March 2027




Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact     Telephone +31 (0)88 781 6000     An agency of the European Union


© European Medicines Agency, 2026. Reproduction is authorised provided the source is acknowledged.

第 2 页

M13B document history

Code                 History                                                          Date

M13B                 Endorsement by the Members of the ICH Assembly                   13 March 2025
                      under Step 2 and release for public consultation.

M13B                 Endorsement by the Regulatory Members of the                     4 August 2026
                      ICH Assembly under Step 4.




ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                                Page 2/23

第 3 页

Table of contents
1. Introduction ....................................................................................................................... 4
1.1. Objective........................................................................................................................... 4
1.2. Background ....................................................................................................................... 4
1.3. Scope ............................................................................................................................... 4

2. Biowaiver criteria for additional strengths ......................................................................... 5
2.1. Selection of biobatch strength(s) .......................................................................................... 5
2.2. Qualitative and quantitative composition between strengths and manufacturing aspects ............. 5
2.2.1. Product composition ......................................................................................................... 5
2.2.2. Manufacturing process ..................................................................................................... 6
2.3. Comparative dissolution ...................................................................................................... 6
2.3.1. Dissolution conditions....................................................................................................... 6
2.3.2. Assessment of similarity ................................................................................................... 8

3. Specific topics .................................................................................................................... 9
3.1. Fixed dose combination drug products .................................................................................. 9
3.2. When In Vivo BE is needed at multiple strengths .................................................................. 10
3.2.1. Bracketing .................................................................................................................... 10
3.3. Drug substance instability ................................................................................................. 10

4. Documentation................................................................................................................. 11

5. Glossary ........................................................................................................................... 11

Annex I: Considerations for deviation from direct compositional proportionality ................ 13

Annex II: Examples of application of additional strengths biowaiver principles .................. 16

Annex III: Decision tree for additional strengths biowaiver for non-high-risk drug products
............................................................................................................................................ 23




ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                                                             Page 3/23

第 4 页

1. Introduction

1.1. Objective

This guideline is intended to provide recommendations on obtaining waivers of bioequivalence (BE)
studies (biowaivers) for one or more additional strengths of a drug product in an application where in
vivo pharmacokinetic (PK) BE or efficacy/safety has been demonstrated for at least one of the
strengths, thereby reducing the need for additional in vivo PK BE studies. This guideline is applicable
during both development and post-approval phases of orally administered immediate-release (IR) solid
dosage forms designed to deliver drugs to the systemic circulation, such as tablets, capsules, and
granules/powders for oral suspension. Deviations from the recommendations in this guideline may be
acceptable if appropriate scientific justification is provided.

1.2. Background

BE for IR solid oral dosage forms with systemic action is largely established via in vivo PK BE studies or
comparative in vitro dissolution studies. For drug products with multiple strengths, if BE has been
demonstrated for at least one of the strengths via in vivo BE study(ies), waivers of in vivo BE
study(ies) may be possible for one or more of the additional strengths based on formulation
proportionality to the strength for which BE has been demonstrated, i.e., the biobatch strength. The
principles in this guideline can also be applied for drug development relating to the introduction of a
new strength(s) relative to the strength used in a pivotal clinical trial, which can be considered as the
biobatch strength.

1.3. Scope

The scientific and technical aspects of study design and data analysis to support BE assessment based
on PK endpoints for orally administered IR solid dosage forms have been described in ICH M13A,
Guideline on Bioequivalence for Immediate-release Solid Oral Dosage Forms.

ICH M13B, the second guideline in the series, describes the scientific and technical aspects of
demonstrating BE for additional strengths of a drug product, i.e., obtaining a biowaiver for one or more
strengths in an application with multiple strengths when BE has been demonstrated for at least one of
the strengths following ICH M13A.

ICH M13B describes the additional strength(s) biowaiver criteria as they relate to a) the PK dose
proportionality of the drug (or drugs in the case of fixed dose combination (FDC) drug products), b)
the formulation proportionality of the drug substance(s) and excipients in the additional strength(s)
compared to the biobatch strength(s), c) the similarity of the method of manufacture, and d) the
similarity in dissolution profiles between the additional strength(s) and the biobatch strength(s) as
demonstrated in the dissolution conditions described in this guideline.

Alternative approaches to demonstrating BE of additional strength(s) such as in vitro-in vivo
correlations (IVIVCs) or other modelling approaches are not discussed in detail in ICH M13B.
Applicants are encouraged to consult the regulatory authority(ies) when an alternative approach is
proposed or taken.

The third guideline in the series, ICH M13C, will include: 1) data analysis and BE evaluation for highly
variable drugs and drugs with narrow therapeutic index, and 2) complex BE study designs and data
analysis considerations, e.g., adaptive BE study design.




ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                           Page 4/23

第 5 页

2. Biowaiver criteria for additional strengths
To be eligible for an additional strengths biowaiver, the following criteria and requirements should be
appropriately addressed.

2.1. Selection of biobatch strength(s)

As detailed in ICH M13A, the selection of biobatch strength(s) is based on the PK proportionality of the
drug (or drugs in the case of an FDC) (see ICH M13A, Section 2.1.6).


2.2. Qualitative and quantitative composition between strengths and
manufacturing aspects

When multiple strengths of a drug product are proposed, a biowaiver for additional strengths may be
possible based on the qualitative and quantitative relationship between the formulation(s) of the
additional strength(s) and the formulation(s) of the biobatch strength(s).

2.2.1. Product composition

The size of the additional strength(s) batch(es) should meet the same criterion as the biobatch
strength(s), as indicated in ICH M13A, Section 2.1.4.

For a biowaiver for additional strength(s), the core formulation(s), i.e., the active and inactive
ingredients that make up a drug product, not including tablet film coating or capsule shell, of the
additional strength(s) should be qualitatively the same as that of the biobatch strength(s). Further, the
core formulation(s) for the additional strength(s) should be quantitatively proportional to that of the
biobatch strength(s), i.e., each strength contains the same ingredients in the same proportion.
Deviations from direct proportionality of the core formulations between the additional strength(s) and
the biobatch strengths(s) can be considered as exceptions with appropriate scientific justification (see
Annex I).

For the purpose of this guideline, the composition of the core formulation(s) of the additional
strength(s) and biobatch strength(s) can be considered proportional when the amount of drug
substance in the formulation, as calculated based on the drug substance form, e.g., the salt, present in
the formulation, is not more than 5% of the drug product core weight in all strengths and the total
core weight remains similar for all strengths (the 5% criterion). Specifically, in this case, a biowaiver
for additional strength(s) may be possible if one of the following conditions is met:

•    The amount of each excipient in the product core is constant between the additional and biobatch
     strength(s) and only the amount of drug substance is different.

•    The amount of diluent/filler varies to account for the difference in the amount of drug substance
     between the additional and biobatch strength(s), while the amount of other excipients remains
     constant.

Excipients included in the core formulation solely to impart colour or flavour, and which are not
expected to affect bioavailability (BA), can generally vary between strengths.

Qualitative differences in non-functional tablet coating/capsule shell composition (other than colourants
or flavours) between the additional strength(s) and the biobatch strength(s) are discouraged and, if
used, should be justified with data to support that the change in tablet coating/capsule shell
composition will not impact BA. Coating (including colourants and flavours) and capsule shell
components do not need to meet the quantitative proportionality conditions.

ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                              Page 5/23

第 6 页

2.2.2. Manufacturing process

The manufacturing process for the additional strength(s) should be representative of that used for the
biobatch strength(s). Specifically, equipment should be of the same type and operating principle, and
differences in process parameters should be limited to those that may be necessary due to a change in
equipment and/or manufacturing scale.

2.3. Comparative dissolution

2.3.1. Dissolution conditions

Similarity of in vitro dissolution should be demonstrated under all conditions between one
representative batch of the additional strength and the biobatch strength. The same batch(es) used in
the BE study(ies), or in the pivotal clinical trials during development of a new drug, should be used for
comparative dissolution testing. In cases where this is not feasible, batches representative of the
formulation and manufacturing process of the biobatch(es) can be considered with appropriate
scientific justification.

The following conditions should be employed in the comparative dissolution studies to characterise the
in vitro dissolution profiles of all strengths of the drug product:

•   Standardised multimedia, i.e., three compendial media covering the range of pH 1.2 - 6.8 (at or
    about pH 1.2, 4.5, and 6.8) under the following conditions:

    o    Apparatus: Compendial paddle or basket apparatuses

    o    Volume of dissolution medium: 900 ml or less

    o    Temperature of the dissolution medium: 37±1°C

    o    Agitation:          paddle apparatus - 50 rpm

                             basket apparatus - 100 rpm

•   Using the quality control (QC) method (unless the method is identical to that described above in
    one of the three compendial media).

At least 12 replicates of the additional strength and biobatch strength should be used for each
dissolution profile determination. For IR oral dosage forms other than tablets or capsules, aliquots of at
least 12 finished product preparations should be evaluated. The same number of replicates should be
used for both strengths being compared.

For suspensions, a rotation speed of 50 rpm is recommended with the paddle apparatus, although a
different rotation speed may be used, if justified.

Surfactant may be used only in the QC method and only when appropriately established as part of
dissolution method development. For gelatin capsules or tablets with gelatin coatings where cross-
linking has been demonstrated, the use of enzymes may be acceptable if appropriately justified.

Samples should be filtered during collection, unless in situ detection methods are used.

Dissolution studies as described above should be conducted and presented even if condition-related
issues are expected or observed, e.g., coning. In these cases, other dissolution conditions, e.g.,
compendial apparatuses and agitation speeds, may be considered to overcome specific issues, if
scientifically justified.



ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                           Page 6/23

第 7 页

Should the initial dissolution studies demonstrate that a complete profile cannot be generated in a
medium, e.g., due to degradation or insolubility of the drug substance, a case-by-case assessment of
the data in that medium is needed. It needs to be determined if the results from that medium can be
excluded from the similarity assessment, e.g., if a profile cannot be generated. Partial profiles may be
assessed if they are demonstrated to be meaningful, e.g., if degradation is evident in the profiles only
after at least three meaningful time points have been collected.

Dissolution conditions should consider the solubility of the drug substance. At pH values where
solubility is limited, complete dissolution may not be achievable for all strengths, and dissolution
profiles may therefore differ between strengths. Such solubility-related differences in dissolution can be
demonstrated by similar dissolution profiles when testing the same dose per vessel, e.g., three tablets
of 5 mg vs. one tablet of 15 mg. If this is not feasible, e.g., due to an excessive number of individual
units in the vessel, the same dissolution behaviour/trend in the comparator product at the same
strengths, e.g., the 5 mg strength of the comparator product vs. the 15 mg strength of the comparator
product compared to the 5 mg strength of the test product vs. the 15 mg strength of the test product,
is considered suitable for confirmation that intrinsic properties of the drug substance, such as pH-
dependent solubility, rather than formulation factors are the cause of the observed initial differences in
dissolution profiles of the different strengths.

The comparative in vitro dissolution experiments should use validated analytical methods that are
suitable for specific use and conditions for the determination of the drug substance. Beyond full
validation in the QC medium, if the analytical method does not employ chromatographic separation of
the analyte from the media components, specificity, linearity, and accuracy should be verified in all
non-QC media. In media where lack of solubility, as established based on solubility data, will prevent
measurable dissolution in a 900 ml volume, verification of the analytical method in that medium is not
necessary.

Dissolution profile similarity testing and any conclusions drawn from the results (see Section 2.3.2),
can be considered valid only if the dissolution profiles have been properly characterised. Dissolution
tests and sampling need not exceed two hours in duration. The additional strength and biobatch
strength dissolution profiles should be composed of identical time points. Sampling time points should
be chosen to adequately describe the complete dissolution profile and have meaningful contribution to
the calculated estimate of the difference between the additional strength and the biobatch strength,
such that the range of measured differences between the profiles is not over-representing areas where
the difference between the additional strength and the biobatch strength dissolution profiles is small
and/or not changing. More frequent sampling during the period of greatest change in the dissolution
profile should be employed. The number of sampling time points will depend on the time it takes to
reach a plateau to estimate dissolution profile similarity. At least three time points are necessary (zero
excluded), although more than three time points are preferred, to describe a dissolution profile, with
the final time point occurring when dissolution reaches ≥85% for either the additional strength or
biobatch strength, or just after both strengths have reached a plateau (of <85%). A plateau is defined
by three successive time points differing by 5% or less in mean absolute values of dissolution across
the three points.

Normally, only the first time point of a plateau should be included in the similarity calculation. However,
in cases where dissolution is slow, care should be taken not to conclude prematurely that the
dissolution profile has reached a plateau. In these cases, dissolution profiles up to two hours should be
collected to assess whether dissolution has truly plateaued or if plateaus, as defined above, are
artefacts related to the slow dissolution behaviour. If a calculated plateau is found to be an artefact,
data points through the artefact and up to a true plateau or completion of dissolution should be
considered in similarity assessment. If, due to limited solubility, a plateau is reached very rapidly, the

ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                             Page 7/23

第 8 页

time points from the plateau needed to assess similarity should be employed, e.g., if plateau is
reached at the second through fourth sampling time, the first three sampling points should be included
in the similarity assessment.

In principle, not more than six time points should be included in the calculation of similarity.

2.3.2. Assessment of similarity

The process for determining dissolution profile similarity for orally administered IR solid dosage forms
is described in the decision tree in Figure 1.

As described in Figure 1, regardless of dissolution variability, when ≥85% of the drug is dissolved
within 15 minutes (very rapid dissolution) for both the additional strength and biobatch strength mean
dissolution profiles, no further mathematical evaluation is needed, and similarity can be concluded.

When less than very rapid dissolution is observed for either the additional strength or biobatch
strength and the standard deviation (SD) is ≤8% across all time points for both strengths, dissolution
similarity can be determined using f2, the estimate of the similarity factor. An f2 value of ≥50 suggests
that the two mean dissolution profiles are similar.

In cases where one strength has mean dissolution ≥85% within 30 minutes (rapid dissolution) and the
other strength has very rapid dissolution, similarity of the profiles should be demonstrated using f2.

High variability is defined as an SD >8% at any time point. If high variability is observed for either the
additional strength or biobatch strength, then calculation of the 90% confidence interval (CI) for the
similarity factor using bootstrapping methodology is recommended. To demonstrate dissolution
similarity, the lower bound of the two-sided 90% bootstrapped CI for the similarity factor should be
≥46 and the median f2 from the bootstrapped samples should be ≥50.

The methods and criteria described above can also be applied when dissolution is incomplete, i.e., not
achieving 85% within two hours. However, when mean dissolution of both the additional strength and
biobatch strength plateau below 10%, no similarity test needs to be applied and similarity can be
assumed.




ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                            Page 8/23

第 9 页

Figure 1: Decision tree for determining mean dissolution profile similarity




3. Specific topics

3.1. Fixed dose combination drug products

For orally administered IR fixed dose combination drug products (FDCs) that consist of multiple
strengths, BE for each individual drug substance should be demonstrated for the strength(s) as
identified in ICH M13A Section 2.1.6. A biowaiver may be possible for the additional strength(s).

When an FDC is formulated as a single blend or granulate (monolithic), the recommendations as
identified in Section 2.2.1 and Annex I are applicable to the proportionality in the formulation(s) of the
additional strength(s). The conditions regarding direct proportionality should be fulfilled for each
individual drug substance in the FDC. When considering the amount of one drug substance in an FDC,
the other drug substance(s) can be considered as if it were an excipient(s), i.e., as if it were a separate
diluent(s)/filler(s) (see Annex II, Example 5 for an illustration of this principle). The proportionality
conditions should still be fulfilled (see Section 2.2.1 and Annex I).

When an FDC is formulated with the individual drug substances separated, e.g., in separate layers of a
tablet or separate particles of a multiparticulate dosage form, the recommendations as identified in
Section 2.2.1 and Annex I are applicable to the proportionality in the formulation(s) of the additional
strength(s), and should be considered independently for each component, e.g., each layer or particle.

When the strengths (or components, if applicable) in an FDC are not proportionally formulated (see
Section 2.2.1 and Annex I), it may be possible to apply a bracketing approach to demonstrate BE for
all strengths (see Section 3.2).

Dissolution data should be submitted for each individual drug substance in the FDC (see Section 2.3).
When it is sufficient to show BE with one FDC strength, this strength is the biobatch strength for
dissolution comparison, and dissolution similarity between the additional strength(s) and the biobatch



ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                              Page 9/23

第 10 页

strength should be demonstrated. The dissolution examples in Section 3.2 for single component drug
products are also applicable to FDC drug products.

3.2. When In Vivo BE is needed at multiple strengths

In vivo BE assessment at multiple strengths is needed when one or more of the following conditions
apply:

•   Dissolution dissimilarity between strengths (see Section 2.3.2);

•   Deviations from direct proportionality in core formulation exceeding those described in Annex I; or

•   Non-dose proportional PK under certain circumstances described in ICH M13A, Section 2.1.6.

Where in vivo BE assessment is needed under both fasting and fed conditions and at multiple
strengths, it may be sufficient to assess BE for only one strength under both conditions. For the other
strengths, a non-high-risk situation may be assumed, and a waiver of either the fasting or fed BE
study may be justified based on prior knowledge and/or PK BE data from studies conducted with the
first strength. The condition selected (fasting or fed) to conduct BE for the second strength should
follow the principles described in ICH M13A, Section 2.1.5.

3.2.1. Bracketing

Assuming qualitative similarity is maintained across strengths, a bracketing approach may be used to
support additional strengths biowaivers when in vivo BE assessment at multiple strengths is needed,
as described above. Under this approach, the strengths selected for in vivo BE assessment represent
the extremes in deviation, such that any differences in the remaining strength(s) are covered by these
extreme strengths. It is therefore sufficient to conduct in vivo BE studies on these extreme strengths,
i.e., biowaiver(s) for the intermediate strength(s) is possible.

For example, in a scenario with three strengths where BE should be demonstrated for more than one
strength due to non-proportional composition, the highest and lowest strengths are considered the
extremes in deviation from direct proportionality, and the intermediate strength is in between with
regard to composition. A bracketing approach may be applied, and in vivo BE studies conducted with
the highest and lowest strengths may be sufficient. The results of these BE studies can be extrapolated
to the intermediate strength based on in vitro dissolution data, where dissolution profile comparison
demonstrates similarity under QC and standardised multimedia conditions appropriate to the situation
under consideration. Both the highest and lowest strengths will serve as biobatch strengths for
dissolution comparison with the intermediate strength. The intermediate strength should demonstrate
similar dissolution to either of the biobatch strengths. Alternatively, the mean dissolution profile of the
intermediate strength should fall between the mean dissolution profiles of the two biobatch strengths,
which may be achieved without demonstrating similarity to either biobatch strength profile individually.

3.3. Drug substance instability

In some cases, drug substance instability may preclude its classification within the Biopharmaceutics
Classification System (BCS), as described in ICH M9, Biopharmaceutics Classification System-based
Biowaivers Sections 2.1 and 2.2. However, for the purpose of an additional strengths biowaiver and to
assign acceptable Level 1 or Level 2 deviations from direct proportionality (see Annex I), applicants
can provide additional data to justify time-dependent high solubility. This can include concentration vs.
time measurements for the drug substance and any degradation products of the drug substance for
the same duration as for the dissolution experiment. If sufficient information cannot be provided to


ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                           Page 10/23

第 11 页

demonstrate time-dependent high solubility, the drug substance should be considered low solubility
within this context.


4. Documentation
Applicants should develop a biowaiver report that includes the following:

•   A rationale for additional strengths biowaiver strategy and biobatch strength(s) selection.

•   A tabular listing of the biobatch strength(s) and the additional strength(s) with their qualitative and
    quantitative compositions, excipient quantity per unit, and quantity of each ingredient as a
    percentage of the total core weight. If deviations from direct proportionality are present, a
    scientific rationale should be provided.

•   A prospective analysis plan for dissolution profile comparison detailing the following:

    o    Objective of the study;

    o    Description of all test methods and media with a thorough description of experimental settings
         and analytical methods, including information on the dissolution conditions such as apparatus,
         de-aeration, filtration during sampling, volume, etc. The analytical method employed should be
         described, including, where necessary, validation and qualification of the analytical
         parameters;

    o    Batch information for the additional and biobatch strengths [unit dose (strength and assay),
         batch number, manufacturing date, batch size, and expiry date (or retest date as
         appropriate)];

    o    Total number of units per strength. Data from at least 12 replicates of each of the additional
         and biobatch strengths should be employed;

    o    Number and distribution of sampling time points; and

    o    Detailed description of method to be used for evaluation of similarity (see Section 2.3.2 and
         Figure 1).

•   The measured pH of each medium at the beginning and end of each dissolution run.

•   Dissolution results with tabulated individual and mean values with standard deviation, as well as
    mean dissolution profiles of the additional and biobatch strengths.

•   Dissolution similarity assessment.

•   Conclusions.


5. Glossary
Biobatch:

A specific batch of a drug product used in BE or pivotal clinical study(ies).

Biobatch strength(s):

The strength(s) of the drug product used in BE or pivotal clinical study(ies).




ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                             Page 11/23

第 12 页

Bootstrapping:

A resampling procedure that uses data from one sample to generate a sampling distribution by
repeatedly taking random samples with replacement from the known sample.

Bracketing approach:

An approach of conducting BE studies on extreme strengths to support the demonstration of BE for all
strengths.

Core formulation:

The active and inactive ingredients that make up a drug product, not including tablet film coating or
capsule shell.

Core weight:

The total mass of the core formulation.

f2 (estimated similarity factor):

F2, the similarity factor, is a model-independent measure for the comparison of two dissolution profiles.




where f2 is the estimated similarity factor, P is the number of time points, Rj is the sample mean
percent biobatch (reference) strength dissolved at jth time after initiation of the study, and Tj is the
sample mean percent test strength dissolved at jth time after initiation of the study.

Fixed dose combination:

A single dosage form that contains two or more drug substances.

IVIVC:

A predictive mathematical model describing the relationship between an in vitro property of a dosage
form (usually the rate or extent of drug dissolution or release) and a relevant in vivo response, e.g.,
plasma drug concentration or amount of drug absorbed.

Non-functional coating:

A coating that does not alter the dissolution and/or release characteristics of the dosage form. For the
purpose of this guideline, coatings designed for functions such as appearance, taste masking, stability,
or strength differentiation are considered non-functional for BE assessment.




ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                            Page 12/23

第 13 页

Annex I: Considerations for deviation from direct
compositional proportionality
Deviations from direct proportionality in core formulations between strengths can be considered as
exceptions with appropriate scientific justification. The rationale for deviations from direct
proportionality should be supported by the pharmaceutical development program for the drug product.
The justification for deviations from direct proportionality should consider the biopharmaceutical
properties of the drug substance(s), the complexity of the formulation and manufacturing
characteristics of the drug product, as well as the dissolution characteristics of the drug product
strengths.

When a rationale for deviation from direct proportionality arises from the pharmaceutical development
program, the BCS-defined solubility characteristics of the drug substance(s) (see ICH M9) will be a
primary factor in determining whether such a deviation can be justified within the context of an
additional strengths biowaiver or whether additional BE data will be necessary to support the deviation.

Deviations from direct proportionality in core formulation for additional strengths containing high
solubility drug substances are lower risk with respect to potential effects on relative BA. Therefore,
with proper justification, deviations in amounts of excipients, based on excipient function, up to Level 2
differences as described in Table 1 can be considered for non-high-risk products (as described in ICH
M13A), provided the absolute value of deviation in total core weight of the additional strength does not
exceed 20% from the theoretical total core weight of the additional strength assuming direct
proportionality, and similarity in mean dissolution profiles is demonstrated with the QC method and
under standardised multimedia conditions (Annex III, Figure 2).

Deviations from direct proportionality in core formulation for additional strength(s) containing low
solubility drug substances are higher risk with respect to potential effects on relative BA and are,
therefore, generally discouraged and need a strong scientific justification. In such a justification,
applicants should explain the pharmaceutical development needs necessitating such a deviation, the
complexity of the drug product, as well as a risk-based evaluation of the mean dissolution profiles
between the additional and biobatch strengths under both QC and standardised multimedia conditions,
as described below.

Non-high-risk drug products

For non-high-risk drug products, deviations from direct proportionality for additional strength(s) can be
accepted if properly justified based on the following:

1) Deviations up to Level 2 differences (see Table 1) can be considered for drug products containing
    BCS low solubility drug substance(s) if:

    a.   similar dissolution is demonstrated with the QC method;

    b.    rapid or very rapid dissolution is demonstrated in at least one of the standardized media
         conditions (see Section 2.3.1). If the QC method is identical to one of the standardized media
         conditions, then demonstration of rapid or very rapid dissolution under that one set of
         dissolution conditions is sufficient; and

    c.   the total core weight of the additional strength does not deviate by more than 20% from the
         theoretical total core weight of the additional strength assuming direct proportionality.

2) Deviations up to Level 1 (see Table 1) can be considered for drug products containing BCS low
    solubility drug substance(s) if:



ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                              Page 13/23

第 14 页

    a.   similar dissolution is demonstrated with the QC method;

    b.   sufficient, i.e., at least 10%, mean dissolution is observed to allow f2 profile comparison under
         at least one standardised multimedia condition other than the QC condition; and

    c.   the total core weight of the additional strength does not deviate by more than 10% from the
         theoretical total core weight of the additional strength assuming direct proportionality.

In all cases, mean dissolution profile comparison should demonstrate similarity in QC and standardised
multimedia conditions.

Refer to Annex III, Figure 2 for biowaiver criteria for non-high-risk drug products.

High-risk drug products

Deviations from direct proportionality for additional strength(s) for drug products containing low
solubility drug substance(s) with formulation-manufacturing (process/technology) enhanced PK
performance are of significant risk with respect to potential effects on relative BA (see ICH M13A
Section 2.1.5). For these high-risk drug products, because of the complexity of the formulations,
excipients functioning as the solubilizing or carrier matrix in the formulation, e.g., the dispersing
excipient(s) in a solid dispersion formulation, should be directly proportional to the drug substance(s)
between the additional and biobatch strengths. For drug products using a solid dispersion intermediate,
proportional amounts of the same intermediate should be used in the different strengths. Deviation
from proportionality for the remaining excipients should only be considered with strong justification
and, if justified, these deviations should fall within Level 1 (see Table 1), provided rapid or very rapid
dissolution is demonstrated in at least one standardised multimedia condition and with the QC method,
and the total core weight of the additional strength does not deviate by more than 10% from the
theoretical total core weight of the additional strength assuming direct proportionality. Mean
dissolution profile comparison should demonstrate similarity in the standardised multimedia conditions
and with the QC method.




ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                              Page 14/23

第 15 页

Table 1: Acceptable Level 1 and Level 2 deviations in core formulation excipient content
relative to the biobatch strength to be considered with appropriate scientific justification for
a biowaiver, expressed as percent (w/w) of the core formulation weight *

Function of excipient                                                         Deviation (%w/w)
                                                                               Level 1        Level 2
Diluent/Filler                                                                5              10
Disintegrant
          Starch                                                               3              6
          Other                                                                1              2
Binder                                                                        0.5            1
Lubricant
          Stearate salts                                                       0.25           0.5
          Others                                                               1              2
Glidant
(Fluidizing agent)
          Talc                                                                 1              2
          Other                                                                0.1            0.2


Total absolute value of excipient changes (%)                                 5              10



* Note to Table 1 - This table provides levels of allowable differences in excipient content when direct
proportionality between the additional and biobatch strengths cannot be achieved. Excipients with
functions not described in the table, e.g., surfactants, should be present in direct proportion between
strengths. For excipients with multiple functions, the most conservative allowable deviation should
apply to that excipient. Deviations from proportionality for these excipients or excipient differences
outside of those described above, are generally not allowed and will need additional supporting
information to provide adequate bridging to the biobatch strength.




ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                                 Page 15/23

第 16 页

Annex II: Examples of application of additional strengths
biowaiver principles
The following cases are theoretical examples meant to illustrate the principles described in the
guideline.

Example 1: Direct proportionality of core formulations

5 mg and 10 mg strengths of a drug product have been developed. A BE study has been conducted
with the 10 mg strength (biobatch strength) comparing it to the 10 mg strength of the accepted
comparator product. As illustrated in the following table, the formulation of the additional strength (5
mg) is directly proportional to the core formulation of the biobatch strength, i.e., each strength
contains the same ingredients in the same proportion. If other biowaiver criteria, including dissolution
similarity, are satisfied, a biowaiver for the 5 mg strength is possible.



Component             Function                         Strength (label claim)                 Absolute % difference
                                                                                               relative to core weight
                                                      10 mg                     5 mg
                                                                                                of additional strength
                                             Biobatch strength         Additional strength
                                             Quantity per unit          Quantity per unit
                                                mg            %*          mg            %*
Dry Mixing
Drug A                Active                  10.0           6.7         5.0           6.7              --
                       ingredient
Lactose                                      128.8         85.9         64.4          85.9             0.0
monohydrate           Diluent/filler

Pregelatinised        Binder                   7.4           4.9         3.7           4.9             0.0
starch
Talc                  Glidant                  3.0           2.0         1.5           2.0             0.0
Lubrication
Magnesium                                      0.8           0.5         0.4           0.5             0.0
                       Lubricant
stearate
Total                                        150.0        100.0         75.0          100.0

Total absolute value of                                                                                0.0
excipient changes (%)
Absolute value of deviation in                                                         0.0
total core weight of additional
strength (%)

*each ingredient expressed as a percentage of the total core weight




ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                                       Page 16/23

第 17 页

Example 2: Acceptable Level 1 deviation from direct proportionality of core formulations

5 mg and 10 mg strengths containing a low solubility drug substance have been developed. A BE study
has been conducted with the 10 mg strength (biobatch strength) comparing it to the 10 mg strength of
the accepted comparator product. Similar mean dissolution has been demonstrated with the QC
method and the three standardised multimedia (more than 10% mean dissolution observed in at least
one of the multimedia) but rapid dissolution is not observed in any of the multimedia.



Component             Function                                Strength (label claim)                        Absolute %
                                                 10 mg                    5 mg                5 mg            difference
                                                                                                           relative to core
                                                Biobatch            Additional           Additional           weight of
                                                strength             strength;           strength;            additional
                                                                      directly             actual              strength
                                                                   proportional         formulation
                                                                    theoretical
                                                                   formulation
                                              Quantity per         Quantity per         Quantity per
                                                 unit                   unit               unit
                                              mg       %*          mg        %*         mg      %*
Dry mixing
Drug A                Active
                                             10.0        6.7        5.0          6.7    5.0          6.2         --
                       ingredient
Lactose
                       Diluent/filler       128.8       85.9       64.4       85.9     69.3      86.6            0.7
monohydrate
Pregelatinised
                       Binder                 7.4        4.9        3.7          4.9    3.7          4.6         0.3
starch
Talc                  Glidant                3.0        2.0        1.5          2.0    1.5          1.9         0.1
Lubrication
Magnesium
                       Lubricant              0.8        0.5        0.4          0.5    0.5          0.6         0.1
stearate
Total                                      150.0      100.0       75.0      100.0     80.0      100.0


Total absolute value of
                                                                                                                 1.2
excipient changes (%)
Absolute relative value of
deviation in total core weight of                                                      6.67
additional strength (%) **
*each ingredient expressed as a percentage of the total core weight

**Absolute relative value of deviation in total core weight between the proposed additional strength
and the directly proportional theoretical formulation of that strength divided by the total weight of the
directly proportional theoretical formulation multiplied by 100, e.g., (80.0-75.0)/75.0 * 100 = 6.67%.



As illustrated in the above table, the formulation of the additional strength (5 mg) deviates from direct
proportionality in core formulation compared to that of the biobatch strength. The %w/w differences
for each excipient comply with the acceptable Level 1 deviations as described in Table 1 and the total
core weight of the additional strength does not deviate by more than 10% from the directly
proportional theoretical total core weight of the additional strength. As illustrated in Annex III, a
biowaiver for the 5 mg strength is possible.




ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                                           Page 17/23

第 18 页

Example 3: Level 1 deviation from direct proportionality of core formulation that does not
meet criteria

5 mg and 10 mg strengths containing a low solubility drug substance have been developed. A BE study
has been conducted with the 10 mg strength (biobatch strength) comparing it to the 10 mg strength of
the accepted comparator product. Similar mean dissolution has been demonstrated with the QC
method and the three standardised multimedia (more than 10% mean dissolution observed in at least
one of the multimedia) but rapid dissolution is not observed in any of the multimedia.



Component             Function                                Strength (label claim)                       Absolute %
                                                                                                             difference
                                                  10 mg                   5 mg                5 mg
                                                                                                             relative to
                                                Biobatch             Additional          Additional        core weight of
                                                strength              strength;          strength;           additional
                                                                       directly            actual             strength
                                                                    proportional        formulation
                                                                     theoretical
                                                                    formulation
                                              Quantity per          Quantity per        Quantity per
                                                 unit                    unit              unit
                                              mg       %*           mg        %*        mg       %*
Dry mixing
Drug A                Active                 10.0       6.7        5.0          6.7    5.0          5.6         --
                       ingredient
Lactose
                       Diluent/filler        128.8      85.9       64.4       85.9     77.6      87.5           1.6
monohydrate
Pregelatinised        Binder
                                              7.4        4.9        3.7          4.9    4.0          4.5        0.4
starch
Talc                  Glidant                3.0        2.0        1.5          2.0    1.5          1.7        0.3
Lubrication
Magnesium
                       Lubricant              0.8        0.5        0.4          0.5    0.6          0.7        0.2
stearate
Total                                       150.0      100.0      75.0      100.0     88.7      100.0


Total absolute value of excipient
                                                                                                                2.5
changes (%)
Absolute value of deviation in
total core weight of additional                                                       18.3
strength (%) **
*each ingredient expressed as a percentage of the total core weight

**Absolute relative value of deviation in total core weight between the proposed additional strength
and the directly proportional theoretical formulation of that strength divided by the total weight of the
directly proportional theoretical formulation multiplied by 100, e.g., (88.7-75.0)/75.0 * 100 = 18.3%.

As illustrated in the above table, the formulation of the additional strength (5 mg) deviates from direct
proportionality in core formulation compared to that of the biobatch strength. The %w/w differences
for each excipient comply with the acceptable Level 1 deviations as described in Table 1, however, the
total core weight of the additional strength deviates by more than 10% from the directly proportional
theoretical total core weight of the additional strength. As illustrated in Annex III, a BE study should be
provided to support the 5 mg strength. Alternative approaches such as an IVIVC or other modelling
approaches to support the 5 mg strength may be considered if agreed by the relevant regulatory
authority(ies).



ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                                          Page 18/23

第 19 页

Example 4: FDC direct proportionality of core formulations

320 mg/25 mg and 160 mg/12.5 mg strengths of a drug product have been developed. A BE study has
been conducted with the 320 mg/25 mg strength (biobatch strength) comparing it to the 320 mg/25
mg strength of the accepted comparator product. As illustrated in the following table, the formulation
of the additional strength (160 mg/12.5 mg) is directly proportional to the core formulation of the
biobatch strength, i.e., each strength contains the same ingredients in the same proportion. If other
biowaiver criteria, including dissolution similarity, are satisfied, a biowaiver for the 160 mg/12.5 mg
strength is possible.

Component            Function                               Strength (label claim)               Absolute % difference
                                                                                                 relative to core weight
                                                  320 mg/25 mg              160 mg/12.5 mg        of additional strength


                                                    Biobatch               Additional strength
                                                     strength
                                                 Quantity per unit          Quantity per unit
                                                   mg           %*            mg        %*
Dry mixing
Drug A               Active ingredient            320.0         56.5        160.0       56.5                --
Drug B               Active ingredient            25.0          4.4          12.5       4.4                 --
Lactose
                     Diluent/filler               200.0         35.3        100.0       35.3               0.0
monohydrate
Pregelatinised                                    10.0          1.8           5.0       1.8               0.0
                     Binder
starch
Talc                 Glidant                      10.0          1.8           5.0       1.8               0.0
Lubrication
Magnesium
                     Lubricant                     1.0          0.2           0.5       0.2                0.0
stearate
Total                                             566.0        100.0        283.0      100.0
Total absolute      value     of   excipient                                                              0.0
changes (%)


Absolute value of deviation in total                                          0.0
core weight of additional strength
(%)
*each ingredient expressed as a percentage of the total core weight




ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                                          Page 19/23

第 20 页

Example 5: FDC that can be considered proportional for core formulations

320 mg/25 mg and 320 mg/12.5 mg strengths of a drug product have been developed. A BE study has
been conducted with the 320 mg/25 mg strength (biobatch strength) comparing it to the 320 mg/25
mg strength of the accepted comparator product. As illustrated in the following table, the formulation
of the additional strength (320 mg/12.5 mg) is not directly proportional to the core formulation
of the biobatch strength, as the amount of drug substance B and the amount of the filler lactose
monohydrate have been changed, while the amount of drug substance A and the amounts of other
excipients and core weight have not been changed, resulting in a different percentage of drug
substance B and lactose monohydrate compared to the biobatch strength (320 mg/25 mg).



Component            Function                                Strength (label claim)                      Absolute %
                                                                                                    difference relative to
                                                                                                  core weight of additional
                                                                                                           strength

                                                    320 mg/25 mg             320 mg/12.5 mg

                                                  Biobatch strength         Additional strength

                                                  Quantity per unit          Quantity per unit
                                                   mg         %*              mg         %*
Dry mixing
Drug A               Active ingredient             320.0         56.5         320.0      56.5                --
Drug B               Active ingredient              25.0         4.4           12.5       2.2              2.2**
Lactose
                     Filler                        200.0         35.3         212.5      37.5               2.2
monohydrate
Pregelatinised
                     Binder                         10.0          1.8         10.0       1.8                0.0
starch
Talc                 Glidant                        10.0          1.8         10.0       1.8                0.0
Lubrication

Magnesium                                           1.0           0.2          1.0       0.2                0.0
                     Lubricant
stearate
Total                                              566.0        100.0         566.0     100.0

Total absolute value of excipient
                                                                                                            2.2
changes (%)
Absolute value of deviation in total
core weight of additional strength (%)
                                                                                         0.0


*each ingredient expressed as a percentage of the total core weight

** not included in the calculation of the total absolute value of excipient changes



When considering drug substance B, the amount of drug substance B is less than 5% of the core
weight in the biobatch strength and the additional strength. According to Section 3.1, the other active
substance, in this case drug substance A, can be considered as if it were an excipient (filler). Hence,
considering drug substance A as if it were a filler, drug substance B follows the 5% criterion, as
indicated in Section 2.2.1, and the additional strength can be considered proportional to the biobatch
strength.




ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                                       Page 20/23

第 21 页

When considering drug substance A, the amount of this active substance is not changed between the
biobatch strength and the additional strength, but drug substance B, in this situation considered as if it
were a filler as described in Section 3.1, is not constant. The ratio between drug substance B and drug
substance A is not the same for both strengths. However, as in this case drug substance B is
considered as if it were a filler and its change represents less than 5% of the product core, which is
compensated by the addition of the same amount of an actual filler of the formulation, the ratio
between drug substance A and ‘filler’ (actual filler + drug substance B) is the same for both strengths.

As a result, the biobatch strength and the additional strength can be considered proportional. If other
biowaiver criteria, including dissolution similarity, are satisfied, a biowaiver for the 320 mg/12.5 mg
strength is possible.



Example 6: Example of bracketing approach for an FDC

Four strengths of a monolithic FDC containing 2 drug substances (drug substance A and drug
substance B) have been developed. The amount of drug substance A in the strengths remains
constant, while the amount of drug substance B varies across strengths. The strengths were all
formulated to the same core weight (see table below).

Component                  Function         Strength (label claim)

                                             40 mg/20 mg          40 mg/15mg           40 mg/10mg      40 mg/5 mg


                                             Quantity per         Quantity per         Quantity per    Quantity per
                                             unit                 unit                 unit            unit
                                             mg         %*        mg         %*        mg      %*      mg       %*
Drug A                     Active           40.0       10.0      40.0       10.0      40.0    10.0    40.0     10.0
                            ingredient
Drug B                     Active           20.0       5.0       15.0       3.75      10.0    2.5     5.0      1.25
                            ingredient
Lactose                    Filler           320.0      80.0      327.0      81.75     334.0   83.5    341.0    85.25
monohydrate
Pregelatinised star        Binder           10.0       2.5       10.0       2.5       10.0    2.5     10.0     2.5
ch
Magnesium                  Lubricant        10.0       2.5       8.0        2.0       6.0     1.5     4.0      1.0
stearate
Total                                       400.0      100.0     400.0      100.0     400.0   100.0   400.0    100.0


*each ingredient expressed as a percentage of the total core weight



The amount of drug substance B is 5% or less of the core weight in the 4 strengths. According to
Section 3.1, the other active substance, in this case drug substance A, can be considered as if it were
an excipient (filler). Considering drug substance A as a filler, drug substance B does not follow the 5%
criterion, as indicated in Section 2.2.1, because the difference in amount of drug substance B is not
compensated by the amount of filler, and the amount of the other excipients, i.e., magnesium stearate,
have not been kept the same. Therefore, the strengths cannot be considered proportional.

When considering drug substance A, the amount of this drug substance is not changed between the 4
different strengths, but drug substance B, which in this situation is considered as if it were a filler as

ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                                        Page 21/23

第 22 页

described in Section 3.1, and the other excipients, i.e., magnesium stearate, are not constant, and
therefore, also in this case, the strengths cannot be considered proportional.

The differences in the formulations of the strengths are bracketed by the highest (40 mg/20 mg) and
lowest (40 mg/5 mg) strengths, and if BE has been demonstrated between the 40 mg/20 mg strength
and the 40 mg/20 mg strength of the accepted comparator product and between the 40 mg/5 mg
strength and the 40 mg/5 mg strength of the accepted comparator product, biowaivers for the
intermediate strengths (40 mg/10 mg and 40 mg/15 mg) may be possible.

As discussed in Section 3.2.1, the intermediate strengths should have similar dissolution compared to
either of these biobatch strengths. Alternatively, if the biobatch strengths have different dissolution
between them, the dissolution profiles of the intermediate strengths should fall within the dissolution
profiles of the two biobatch strengths.




ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                          Page 22/23

第 23 页

Annex III: Decision tree for additional strengths biowaiver
for non-high-risk drug products
The decision tree below should be followed to determine whether a biowaiver is possible for an
additional strength for non-high-risk drug products.

Figure 2: Decision tree with recommendations for additional strengths biowaiver for non-
high-risk drug products




* The additional strength should be supported with a BE study(ies). In some situations, a bracketing
approach may be applicable (see Section 3.2.1). Alternatively, additional information including an
IVIVC or other modelling approaches to support the additional strength may be considered if agreed by
the relevant regulatory authority(ies).

** Core weight deviation – refers to the % deviation of the total core weight of the additional strength
relative to the theoretical total core weight of the additional strength assuming direct proportionality
(see Annex I).




ICH M13B Guideline on bioequivalence for immediate-release solid oral dosage forms -
additional strengths biowaiver
EMA/CHMP/ICH/85092/2025                                                                          Page 23/23

来源:EMA 官方医药监管信息 · ema.europa.eu